Innovative Access Solutions ‘Paving The Way’ To European Reimbursement For CSL’s Hemgenix

CSL Behring explains how it worked with authorities in Denmark, Austria, England, Scotland, Spain and Switzerland to secure innovative access arrangements suitable to each nation’s “unique needs” for its one-time gene therapy, Hemgenix.